The Hematologist

banner image

The Year's Best in Sickle Cell Disease

Dr. DeBaun covers updates from 2016 in the treatment of SCD and discusses the potential availability of a new therapy for preventing vaso-occlusive pain episodes.

Read more
banner image

Improving Ability to Treat Patients with Qualitative and Quantitative Platelet Disorders

Dr. Garcia looks at the best of 2016 in the field of platelet disorders.

Read more
banner image

BTK Inhibition Saunters to the Front of the Line in CLL

Dr. Moss covers updates in the management of the most common subtype of leukemia (CLL), focusing on the value of BTK inhibition.

Read more
Current Issue Static Feature

Current Issue

November/December 2016              
Volume 13, Issue 6

Read current issue

President's Column

Dr Charles Abrams - new designProfessor of Medicine, Pathology, and Laboratory Medicine; Director PENN-CHOP Blood Center for Patient Care and Discovery, Philadelphia, PA
A High Note for Grand Goals
November 1, 2016

Dr. Charles Abrams talks about the Society's accomplishments during 2016 and initiatives on the horizon made possible by ASH members.

View all president's column articles

  • DEA Eliminates Grace Period for Registration Renewal
    December 21, 2016

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model
    December 20, 2016

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells
    November 23, 2016

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

  • 2016 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
    November 17, 2016

    The American Society of Hematology (ASH) is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with the disease, both in the United States and globally.

View all Policy News